Yogender Garg, MD
Ophthalmology · Oxnard, CANPI 1508870700
Payments from drug & device makers
Across 326 payments — averaging $126.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$30K
- AbbVie$3K
- Alcon$3K
- Regeneron Healthcare Solutions, Inc.$822
- Glaukos Corporation$747
- Nova Eye, Inc.$537
- plus $4K from 25 others
What the payments were for
- Travel & lodging$280%
- Food & beverage$11,01099%
- Gifts$450%
- Entertainment$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 16 | $30,125 |
| AbbVie(2 entities) | 122 | $2,806 |
| Alcon | 64 | $2,542 |
| Regeneron Healthcare Solutions, Inc. | 17 | $822 |
| Glaukos Corporation | 13 | $747 |
| Nova Eye, Inc. | 2 | $537 |
| Sun Pharmaceutical Industries Inc. | 11 | $430 |
| Bausch & Lomb Americas Inc. | 12 | $349 |
| Genentech USA, Inc. | 12 | $304 |
| Aerie Pharmaceuticals, Inc. | 3 | $275 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $266 |
| Ellexiscience | 1 | $235 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $225 |
| Kala Pharmaceuticals, Inc. | 5 | $202 |
| Novartis | 5 | $185 |
| Silk Road Medical, Inc. | 1 | $145 |
| Astellas Pharma US Inc | 2 | $141 |
| Amgen | 1 | $126 |
| Sight Sciences, Inc. | 7 | $117 |
| AstraZeneca | 1 | $88 |
| Akorn, Inc. | 4 | $85 |
| Harrow Eye, LLC | 2 | $62 |
| Thea Pharma Inc. | 3 | $61 |
| Optos, Inc. | 3 | $58 |
| Apellis Pharmaceuticals, Inc. | 2 | $44 |
| Oyster Point Pharma, Inc. | 1 | $32 |
| Tarsus Pharmaceuticals, Inc. | 1 | $26 |
| Quidel Corporation | 1 | $20 |
| Akorn Operating Company LLC | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$656
- XEN GLAUCOMA TREATMENT SYSTEM$472
- Rhopressa$370
- Clareon$316
- enVista MX60 IOL$256
- EYLEA$245
- CEQUA$234
- EYLEA HD$227
- ARGOS$221
- Hydrus Microstent$164
- ENROUTE Transcarotid Neuroprotection System$145
- ENROUTE Transcarotid Stent System$145
- ENHANCE Transcarotid Peripheral Access Kit$145
- ENROUTE 0.014 Guidewire$145
- Clareon PanOptix Pro$135
- enVista Aspire IOL$128
- TEPEZZA$126
- XEN$125
- INVELTYS$124
- iStent inject Trabecular Micro-Bypass Stent System$123
How this compares
$41,108 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 200 | $250,550 |
| LumiganBimatoprost | 570 | $239,165 |
| Cyclosporine | 204 | $96,812 |
| MieboPerfluorohexyloctane/Pf | 77 | $74,673 |
| RocklatanNetarsudil Mesylat/Latanoprost | 81 | $47,419 |
| CequaCyclosporine | 45 | $44,391 |
| Alphagan PBrimonidine Tartrate | 151 | $39,874 |
| XiidraLifitegrast | 28 | $37,551 |
| VyzultaLatanoprostene Bunod | 41 | $18,107 |
| RhopressaNetarsudil Mesylate | 25 | $11,076 |
| Brimonidine Tartrate | 180 | $10,257 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 31 | $6,176 |
| Prednisolone Acetate | 220 | $5,746 |
| Travoprost | 20 | $4,658 |
| MoxifloxacinMoxifloxacin Hcl | 203 | $4,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $2,806 | $529,589921 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $349 | $130,331146 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $275 | $58,495106 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $430 | $44,39145 claims |
| AlconSimbrinza | $2,542 | $6,17631 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $266 | $2,09914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Oxnard
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.